Executive summary: Select findings, conclusions, and policy recommendations

Clinical Infectious Diseases

Volumn 41, Issue 4 SUPPL., 2005, Pages

  Chea, Phakdey ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; BETA LACTAMASE; MACROLIDE; MEROPENEM; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPECTINOMYCIN; TETRACYCLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; BACTERIAL PNEUMONIA; EPIDEMIC; GONORRHEA; HAEMOPHILUS INFLUENZAE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; MALARIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NEISSERIA GONORRHOEAE; PENICILLIN RESISTANCE; PRIORITY JOURNAL; SEPSIS; SEPTICEMIA; SHORT SURVEY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TUBERCULOSIS; URINARY TRACT INFECTION;

BETA-LACTAMASES; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; COST OF ILLNESS; DRUG INDUSTRY; DRUG RESISTANCE; HEALTH PLANNING GUIDELINES; HEALTH POLICY; HUMANS; POPULATION SURVEILLANCE; WORLD HEALTH;

EID: 23244461578     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/430781     Document Type: Short Survey

References (14)

1. Low DE. Changing trends in antimicrobial-resistant pneumococci: it's not all bad news. Clin Infect Dis 2005; 41(Suppl 4):S228-33 (in this supplement).
2. Rennie RP, Ibrahim KH. Antimicrobial resistance in Haemophilus influenzae: how can we prevent the inevitable? Commentary on antimicrobial resistance in H. influenzae based on data from the TARGETed surveillance program. Clin Infect Dis 2005; 41(Suppl 4):S234-8 (in this supplement).
3. Vella S, Palmisano L. The global status of resistance to antiretroviral drugs. Clin Infect Dis 2005; 41(Suppl 4):S239-46 (in this supplement).
4. Olliaro P. Drug resistance hampers our capacity to roll back malaria. Clin Infect Dis 2005; 41(Suppl 4):S247-57 (in this supplement).
5. Aziz MA, Wright A. The World Health Organization/International Union against Tuberculosis and Lung Disease Global Project on Surveillance for Anti-Tuberculosis Drug Resistance: a model for other infectious diseases. Clin Infect Dis 2005; 41(Suppl 4):S258-62 (in this supplement).
6. Tapsall JW. Antibiotic resistance in Neisseria gonorrhoeae. Clin Infect Dis 2005; 41(Suppl 4):S263-8 (in this supplement).
7. Weber JT. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2005; 41(Suppl 4):S269-72 (in this supplement).
8. Turner PJ. Extended-spectrum β-lactamases. Clin Infect Dis 2005; 41(Suppl 4):S273-5 (in this supplement).
9. Fritsche TR, Sader HS, Toleman MA, Walsh TR, Jones RN. Emerging metallo-β-lactamase-mediated resistances: a summary report from the worldwide SENTRY Antimicrobial Surveillance Program. Clin Infect Dis 2005; 41(Suppl 4):S276-8 (in this supplement).
10. Jones RN, Biedenbach DJ, Sader HS, Fritsche TR, Toleman MA, Walsh TR. Emerging epidemic of metallo-beta-lactamase-mediated resistances. Diagn Microbiol Infect Dis 2005; 51:77-84.
11. Koeth LM, Miller LA. Evolving concepts of pharmaceutical company-sponsored surveillance studies. Clin Infect Dis 2005; 41(Suppl 4): S279-82 (in this supplement).
12. Howard DH, Scott RD II. The economic burden of drug resistance. Clin Infect Dis 2005; 41(Suppl 4):S283-6 (in this supplement).
13. Barza M, Gorbach SL, eds. The need to improve antimicrobial use in agriculture: ecological and human health consequences: a report of the facts about antibiotics in animals and the impact on resistance (FAAIR) project-The Alliance for the Prudent Use of Antibiotics. Clin Infect Dis 2002; 34(Suppl 3):S71-144.
14. Levy SB. The antibiotic paradox: how the misuse of antibiotics destroys their curative powers. 2nd ed. Cambridge, MA: Perseus Publishing, 2002.